Alembic Recalls Aripiprazole Tablets Due to Labeling Error
Alembic Pharmaceuticals is recalling aripiprazole tablets because bottles labeled as 2 mg contained 5 mg tablets. The error affects 19,153 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II due to a labeling error involving a dosage discrepancy. Per the rubric, minor labeling errors and low-risk contamination without reported serious injury fall under the Moderate severity category.
Plain-English summary
Alembic Pharmaceuticals Limited is recalling 19,153 bottles of Aripiprazole Tablets, USP, 2 mg, 30 count. The recall was initiated due to a labeling error where bottles labeled as containing 2 mg tablets actually contained aripiprazole 5 mg tablets, 100 count.
The affected product is identified by Lot 1905003298 with an expiration date of 01/31/2021. The product was distributed nationwide in the U.S. The agency has classified this recall as Class II, indicating a situation in which use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences.
Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product is found, it should be returned to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider if they have questions regarding their medication.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Alembic Pharmaceuticals Limited
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 19,153
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 1905003298 Exp. 01/31/2021
UPCs (1)
- 0362332097302
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole 30mg bottle contained voriconazole 50mg tablets instead
FDA (Drugs) · 2026-06-24
- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- HighAripiprazole 20 mg Tablets Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Alembic Pharmaceuticals Limited
See all →- ModerateFesoterodine extended-release tablets recalled over a diester impurity above specification
FDA (Drugs) · 2026-01-14
- ModerateFesoterodine tablets recalled after a diester impurity exceeded its specification limit
FDA (Drugs) · 2025-11-26
- HighDoxepin hydrochloride capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- SevereCelecoxib Capsules 200 mg recalled for foreign tablets inside bottles
FDA (Drugs) · 2025-06-18
- ModerateBromfenac Ophthalmic Solution 0.09% Recalled for Failed Impurities Specifications
FDA (Drugs) · 2025-06-04
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02